Examkin

Soru

Zorluk: ZorMonitoring and Treatment Evaluation

A 59-year-old man presents to the clinic for follow-up of Crohn's disease and gout. His Crohn's disease has been well-controlled for the past three years on a stable dose of azathioprine (150 mg daily). However, he has experienced three severe gout flares over the last six months. He brings a new prescription for allopurinol 100 mg daily from his rheumatologist and asks for advice regarding the safety of combining these medications before taking his first dose. His current laboratory results, including a complete blood count and comprehensive metabolic panel, are within normal limits. Which of the following is the most appropriate next step in the management of this patient's medication regimen?

  1. A
    Maintain the current dose of azathioprine and initiate allopurinol as prescribed
  2. Reduce the azathioprine dose to approximately one-quarter of its current amountCevap
  3. C
    Withhold allopurinol until the patient experiences another acute gout flare
  4. D
    Order a thiopurine methyltransferase activity assay to guide the dose adjustment
  5. E
    Substitute azathioprine with 6-mercaptopurine to bypass the pharmacokinetic interaction

Cevap

Reduce the azathioprine dose to approximately one-quarter of its current amount
Azathioprine is a prodrug that is converted into 6-mercaptopurine (6-MP). 6-MP is subsequently metabolized by three primary enzymatic pathways: xanthine oxidase (XO) to inactive thiouric acid, thiopurine methyltransferase (TPMT) to inactive methyl-mercaptopurine, and hypoxanthine-guanine phosphoribosyltransferase (HGPRT) to active 6-thioguanine nucleotides (6-TGN). Allopurinol is an XO inhibitor. When administered concurrently with azathioprine, allopurinol blocks the inactivation of 6-MP, drastically shunting its metabolism toward the production of 6-TGN. High intracellular levels of 6-TGN can cause severe, potentially life-threatening myelosuppression. Therefore, when initiating allopurinol in a patient already taking azathioprine, the azathioprine dose must be preemptively reduced to 25% to 33% (approximately one-quarter) of its original dose, and complete blood counts should be monitored closely.

Adım Adım Çözüm

1
Analyze the patient's current medication regimen and the newly prescribed drug.
The patient is taking azathioprine and is about to start allopurinol for recurrent gout.
Identifying potential drug-drug interactions is critical before initiating new therapies, especially with immunosuppressants.
2
Identify the specific pharmacokinetic interaction between the two medications.
Allopurinol is a xanthine oxidase inhibitor. Azathioprine is converted to 6-mercaptopurine, which relies on xanthine oxidase for metabolism into inactive thiouric acid.
Understanding the metabolic pathways helps predict the clinical consequence of the interaction.
3
Determine the clinical consequence of this enzymatic inhibition.
Inhibition of xanthine oxidase shunts 6-mercaptopurine metabolism toward the production of active, toxic 6-thioguanine nucleotides (6-TGN), leading to severe bone marrow suppression.
This identifies the risk of life-threatening toxicity if both drugs are taken at standard doses.
4
Select the appropriate evidence-based management strategy.
The dose of azathioprine must be preemptively reduced to 25% to 33% of its original dose to prevent toxicity while maintaining efficacy.
This allows the patient to safely benefit from both therapies without risking severe myelosuppression.

Anahtar Kavram

Pharmacokinetic interaction between azathioprine/6-mercaptopurine and xanthine oxidase inhibitors
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru